MILFORD, Mass.--(BUSINESS WIRE)--SeraCare Life Sciences, Inc. (NASDAQ: SRLS) announced today the addition of differentiated Cryo-M Human Monocytes to their AccuCell™ peripheral blood mononuclear cell (PBMC) portfolio. SeraCare’s Cryo-M cells provide researchers with a high quality, specialized and unstimulated cell line to study gene expression, immune and inflammatory responses. This product is manufactured from standardized, quality-controlled sole source lots, allowing for consistent and reproducible results. This is the third in a series of new cellular products and the twenty-first new product introduced to SeraCare’s overall portfolio over the last 18 months.
